AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34112100 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical testosterone
Number of subjects: 195
Study 34112100 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based intimate lubricant gel
Number of subjects: 195
Study 34112100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dilators
Number of subjects: 195
Study 33128480 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐tPCS at 75 Hz
Number of subjects: 15
Study 33128480 — intervention group
Group type: EXPERIMENTAL
Intervention: c‐tPCS at 4 Hz
Number of subjects: 15
Study 33128480 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 15
Study 36287636 — intervention group
Group type: EXPERIMENTAL
Intervention: PGT-A
Number of subjects: 0
Study 36287636 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF (Control)
Number of subjects: 0
Study 33450831 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation program (4 weeks, 16 hours)
Number of subjects: 0
Study 32575151 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention (immersive video content as a distraction method)
Number of subjects: 40
Study 32575151 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 40
Study 32706100 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (n = 63)
Number of subjects: 126
Study 32706100 — intervention group
Group type: COMPARATOR
Intervention: Control (nil intervention, n = 63)
Number of subjects: 126
Study 35985037 — intervention group
Group type: EXPERIMENTAL
Intervention: 50000 IU/w vitamin D3 for 12 weeks
Number of subjects: 46
Study 35985037 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 46
Study 35985037 — intervention group
Group type: EXPERIMENTAL
Intervention: 50000 IU/w vitamin D3 for 12 weeks (second phase)
Number of subjects: 46
Study 33694031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayahuasca (N = 14)
Number of subjects: 30
Study 33694031 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 16)
Number of subjects: 30
Study 36249225 — intervention group
Group type: EXPERIMENTAL
Intervention: Wristband tracker (Withings Pulse HR) for 3 weeks
Number of subjects: 150
Study 36249225 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermometer patch (Tucky thermometer) for 3 weeks
Number of subjects: 150
Study 35019120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer Lactate (RL) group
Number of subjects: 80
Study 35019120 — intervention group
Group type: COMPARATOR
Intervention: Physiologic Solution (PS) group
Number of subjects: 80
Study 33321462 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab plus FOLFOX followed by maintenance with panitumumab
Number of subjects: 196
Study 33321462 — intervention group
Group type: COMPARATOR
Intervention: Panitumumab + 5‐FU/LV
Number of subjects: 196
Study 33321462 — intervention group
Group type: COMPARATOR
Intervention: Single-agent panitumumab
Number of subjects: 196
Study 33321462 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PRESSING panel and response dynamics
Number of subjects: 196
Study 33074769 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Release (SR) tablets of isradipine composed of 15.0% (wt/wt) HPMC
Number of subjects: 0
Study 33074769 — intervention group
Group type: COMPARATOR
Intervention: Immediate Release (IR) tablets of isradipine
Number of subjects: 0
Study 33402409 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg daily or 30 mg daily if patients had dose-reduction criteria)
Number of subjects: 220
Study 33402409 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) using aspirin (100 mg daily) plus clopidogrel (75 mg daily) for 6 months
Number of subjects: 220
Study 33402409 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 220
Study 33402409 — intervention group
Group type: COMPARATOR
Intervention: DAPT
Number of subjects: 220
Study 35905861 — intervention group
Group type: EXPERIMENTAL
Intervention: Kind acts for others
Number of subjects: 182
Study 35905861 — intervention group
Group type: EXPERIMENTAL
Intervention: Kind acts for themselves
Number of subjects: 182
Study 35905861 — intervention group
Group type: COMPARATOR
Intervention: Control (listing daily activities)
Number of subjects: 182
Study 33757537 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tube clearance (ATC) using a 28F PleuraFlow device
Number of subjects: 520
Study 33757537 — intervention group
Group type: COMPARATOR
Intervention: Standard drainage (conventional chest tube)
Number of subjects: 520
Study 33293310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard physical work during early working life (standing/walking work with lifting/carrying)
Number of subjects: 5909
Study 33293310 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard physical work during early working life (heavy or fast work that is physically strenuous)
Number of subjects: 5909
Study 33293310 — intervention group
Group type: COMPARATOR
Intervention: Sedentary work during early working life
Number of subjects: 5909
Study 35718262 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta variant group (vaccination period)
Number of subjects: 1121
Study 34090987 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET) 3× weekly for 6 months
Number of subjects: 210
Study 34090987 — intervention group
Group type: COMPARATOR
Intervention: Control group (1× weekly health lectures)
Number of subjects: 210
Study 34090987 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET)
Number of subjects: 210
Study 36168693 — intervention group
Group type: EXPERIMENTAL
Intervention: Picamilon Ginkgo
Number of subjects: 278
Study 36168693 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba extract
Number of subjects: 278
Study 35449015 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily
Number of subjects: 25210
Study 35449015 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 25210
Study 34236915 — intervention group
Group type: COMPARATOR
Intervention: Triple antithrombotic therapy with clopidogrel
Number of subjects: 65
Study 34236915 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy with potent P2Y12 inhibitors (ticagrelor or prasugrel)
Number of subjects: 65
Study 32114213 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotized needle holder (JAIMY; Endocontrol, Grenoble, France)
Number of subjects: 20
Study 32114213 — intervention group
Group type: COMPARATOR
Intervention: Conventional needle holders
Number of subjects: 20
Study 35353300 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Cuff Closure Model (VC)
Number of subjects: 30
Study 35353300 — intervention group
Group type: COMPARATOR
Intervention: dV-Trainer® (VR)
Number of subjects: 30
Study 35353300 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-completion survey
Number of subjects: 30
Study 32948369 — intervention group
Group type: COMPARATOR
Intervention: HLA-DRB1*01:02 allele frequency in COPD patients (6.54%)
Number of subjects: 214
Study 32948369 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*01:02
Number of subjects: 214
Study 32948369 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*15:01
Number of subjects: 214
Study 32762229 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional ultrapulsed CO2 laser (group L, n=30)
Number of subjects: 60
Study 32762229 — intervention group
Group type: COMPARATOR
Intervention: High‐intensity focused ultrasound (group U, n=30)
Number of subjects: 60
Study 34971723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 24
Study 34971723 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (30 μg/kg)
Number of subjects: 24
Study 34971723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 24
Study 33068444 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab low dose (LD: 75/75/150 mg)
Number of subjects: 162
Study 33068444 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab high dose (HD: 75/150/300 mg)
Number of subjects: 162
Study 33068444 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab low dose (LD)
Number of subjects: 162
Study 33068444 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab high dose (HD)
Number of subjects: 162
Study 33068444 — intervention group
Group type: COMPARATOR
Intervention: Etanercept (0.8 mg/kg up to a max of 50 mg)
Number of subjects: 162
Study 33068444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 32243575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B iO electric toothbrush
Number of subjects: 0
Study 32243575 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 0
Study 32243575 — intervention group
Group type: COMPARATOR
Intervention: Sonic toothbrush
Number of subjects: 0
Study 32995960 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (SL; simulated altitude/end-exercise arterial oxygen saturation=0 m/96%)
Number of subjects: 11
Study 32995960 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypoxia (MH; 2200 m/90%)
Number of subjects: 11
Study 32995960 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoxia (SH; 4200 m/79%)
Number of subjects: 11
Study 32995960 — intervention group
Group type: COMPARATOR
Intervention: Muscle oxygenation in MH compared to SL
Number of subjects: 11
Study 32995960 — intervention group
Group type: COMPARATOR
Intervention: Muscle oxygenation in SH compared to SL
Number of subjects: 11
Study 32995960 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak twitch amplitude with single and paired electrical stimuli
Number of subjects: 11
Study 32995960 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal torque during brief and sustained MVCs
Number of subjects: 11
Study 32995960 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary activation measured using transcranial magnetic stimulation
Number of subjects: 11
Study 33372745 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin adjusted to anti‐Xa level of 0.2‐0.5 international units/mL started at less than 24 hours after insertion of central venous catheter
Number of subjects: 47
Study 33372745 — intervention group
Group type: COMPARATOR
Intervention: Usual care without placebo
Number of subjects: 47
Study 36268462 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs) - apixaban, edoxaban, rivaroxaban
Number of subjects: 0
Study 36268462 — intervention group
Group type: COMPARATOR
Intervention: Apixaban and rivaroxaban
Number of subjects: 0
Study 32692240 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved Hospital Elderly Life Program (HELP) combined with conventional nursing for 2 weeks
Number of subjects: 106
Study 35920133 — intervention group
Group type: EXPERIMENTAL
Intervention: dilpacimab + FOLFIRI
Number of subjects: 66
Study 35920133 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab + FOLFIRI
Number of subjects: 66
Study 33177129 — intervention group
Group type: EXPERIMENTAL
Intervention: Visualisation and pictorial representation of abdominal aortic calcification (AAC) results at baseline
Number of subjects: 0
Study 33177129 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group receiving AAC results at 12 weeks
Number of subjects: 0
Study 32720783 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise intervention (DEI, N=27)
Number of subjects: 60
Study 32720783 — intervention group
Group type: COMPARATOR
Intervention: Diet only intervention (DI, N=27)
Number of subjects: 60
Study 32456646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing impairment (measured by asking participants if they had hearing problems)
Number of subjects: 1248
Study 32456646 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of hearing impairment (identified by pure tone average of hearing thresholds at 0.5, 1, 2, and 4 kHz)
Number of subjects: 1248
Study 36453014 — intervention group
Group type: EXPERIMENTAL
Intervention: G-Rup® syrup (30 ml twice daily for 12 weeks)
Number of subjects: 0
Study 36453014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34842573 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenase (intravenous selenium) for 5 days
Number of subjects: 50
Study 34842573 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) for 5 days
Number of subjects: 50
Study 34566855 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rESWT
Number of subjects: 100
Study 34566855 — intervention group
Group type: COMPARATOR
Intervention: Sham-placebo rESWT
Number of subjects: 100
Study 35197060 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated baby wraps
Number of subjects: 50
Study 35197060 — intervention group
Group type: COMPARATOR
Intervention: Untreated baby wraps (control)
Number of subjects: 50
Study 33609741 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Eye Movement (REM) sleep
Number of subjects: 0
Study 32063531 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial removable dental prosthesis (PRDP) group (n=79)
Number of subjects: 150
Study 32063531 — intervention group
Group type: COMPARATOR
Intervention: Shortened dental arch (SDA) group (n=71)
Number of subjects: 150
Study 33891831 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, n = 713
Number of subjects: 2612
Study 33891831 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, n = 751
Number of subjects: 2612
Study 33891831 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal polyps presence
Number of subjects: 2612
Study 33891831 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 2612
Study 33891831 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical factors (laboratory differences, time from collection to analysis)
Number of subjects: 2612
Study 32894044 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 238
Study 32894044 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 238
Study 32894044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 33009352 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity resistance exercise (3 sets of 10 repetitions at 68% 1RM)
Number of subjects: 9
Study 33009352 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (4 sets of 6 repetitions at 85% 1RM)
Number of subjects: 9
Study 33009352 — intervention group
Group type: COMPARATOR
Intervention: Rest (no exercise)
Number of subjects: 9
Study 33592868 — intervention group
Group type: EXPERIMENTAL
Intervention: A+HA (20 mL daily for 8 weeks)
Number of subjects: 47
Study 33592868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL daily for 8 weeks)
Number of subjects: 47
Study 32769414 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz spinal cord stimulation (10 kHz-SCS)
Number of subjects: 0
Study 32769414 — intervention group
Group type: COMPARATOR
Intervention: Low-frequency spinal cord stimulation (LF-SCS)
Number of subjects: 0
Study 36306168 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA (2 U/kg for cycle 1 only, 8 U/kg and 16 U/kg) followed by a tailored home exercises therapy programme
Number of subjects: 0
Study 36306168 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA treatment cycles
Number of subjects: 0
Study 34955131 — intervention group
Group type: EXPERIMENTAL
Intervention: HFNC
Number of subjects: 44
Study 34955131 — intervention group
Group type: COMPARATOR
Intervention: NIPPV
Number of subjects: 44
Study 36907876 — intervention group
Group type: EXPERIMENTAL
Intervention: Little ACF (intervention)
Number of subjects: 0
Study 36907876 — intervention group
Group type: COMPARATOR
Intervention: Four digital lectures about child development and parenting (active control)
Number of subjects: 0
Study 33680312 — intervention group
Group type: EXPERIMENTAL
Intervention: Blindfolded training (BT)
Number of subjects: 85
Study 33680312 — intervention group
Group type: COMPARATOR
Intervention: Standard training (ST)
Number of subjects: 85
Study 34285430 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative respiratory rehabilitation (group A)
Number of subjects: 19
Study 34285430 — intervention group
Group type: COMPARATOR
Intervention: Postoperative rehabilitation only (group B)
Number of subjects: 19
Study 34285430 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 35007482 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-administered hypnosis (Group A) for 8 weeks
Number of subjects: 70
Study 35007482 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis (Group B) for 8 weeks
Number of subjects: 70
Study 34840503 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Pharmacy-Based Intervention (CPBI)
Number of subjects: 100
Study 34840503 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 100
Study 32312261 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger extract 500 mg
Number of subjects: 80
Study 32312261 — intervention group
Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 80
Study 35481442 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 20 mg/kg
Number of subjects: 47
Study 35481442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 32581409 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) therapy
Number of subjects: 32
Study 32581409 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive positive pressure ventilation (NPPV)
Number of subjects: 32
Study 36181471 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg (or maximum-tolerated dose)
Number of subjects: 55
Study 36181471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 36181471 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 55
Study 34467796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent theta burst stimulation (iTBS); applied over the left dorsolateral prefrontal cortex for 10 consecutive weekdays.
Number of subjects: 35
Study 34467796 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation; applied over the left dorsolateral prefrontal cortex for 10 consecutive weekdays.
Number of subjects: 35
Study 33346522 — intervention group
Group type: EXPERIMENTAL
Intervention: LVS (daytime serum and nighttime serum) with basic skin care regimen (moisturizer and SPF 35 sunscreen)
Number of subjects: 61
Study 33346522 — intervention group
Group type: COMPARATOR
Intervention: Basic skin care regimen only (control)
Number of subjects: 61
Study 35040798 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable technology-assisted combined home-based exercise program
Number of subjects: 55
Study 35040798 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 55
Study 35113899 — intervention group
Group type: EXPERIMENTAL
Intervention: Active patient participation during rehabilitation
Number of subjects: 108
Study 35113899 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation session type
Number of subjects: 108
Study 35113899 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy-led rehabilitation sessions
Number of subjects: 108
Study 33531563 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced-learning (2-h weekly sessions over 4 weeks)
Number of subjects: 42
Study 33531563 — intervention group
Group type: COMPARATOR
Intervention: Mass-learning (single 8-h session)
Number of subjects: 42
Study 33531563 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 35790787 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus abiraterone
Number of subjects: 1058
Study 35790787 — intervention group
Group type: COMPARATOR
Intervention: ADT with placebo
Number of subjects: 1058
Study 34425666 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.12% SPDD alcohol free
Number of subjects: 84
Study 34425666 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.20% SPDD alcohol free
Number of subjects: 84
Study 34425666 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.12% alcohol free with ADS
Number of subjects: 84
Study 34425666 — intervention group
Group type: EXPERIMENTAL
Intervention: CHX 0.20% alcohol free with ADS
Number of subjects: 84
Study 33895559 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucaloric ketogenic diet (EKD)
Number of subjects: 102
Study 33895559 — intervention group
Group type: COMPARATOR
Intervention: Eucaloric standard diet
Number of subjects: 102
Study 35917059 — intervention group
Group type: EXPERIMENTAL
Intervention: macitentan 10 mg
Number of subjects: 492
Study 35917059 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 492
Study 33843297 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription (n=72)
Number of subjects: 141
Study 33843297 — intervention group
Group type: COMPARATOR
Intervention: Advice session (n=69)
Number of subjects: 141
Study 33843297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study 34386824 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical exposure with orthodontic treatment
Number of subjects: 120
Study 34386824 — intervention group
Group type: COMPARATOR
Intervention: Closed surgical exposure with orthodontic treatment
Number of subjects: 120
Study 33348644 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive abutment (DEF)
Number of subjects: 147
Study 33348644 — intervention group
Group type: COMPARATOR
Intervention: Healing abutment (HEA)
Number of subjects: 147
Study 33348644 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mm high abutment (Subgroup A)
Number of subjects: 147
Study 33348644 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mm high abutment (Subgroup B)
Number of subjects: 147
Study 35364630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 50
Study 35364630 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 50
Study 33632347 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Intensive Motivational Estimated Risk tool (TIMER)
Number of subjects: 160
Study 33632347 — intervention group
Group type: COMPARATOR
Intervention: 5 A's intervention
Number of subjects: 160
Study 33147593 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed test surfaces
Number of subjects: 48
Study 33147593 — intervention group
Group type: COMPARATOR
Intervention: Control group (not sealed)
Number of subjects: 48